Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rahul Banerjee, a myeloma specialist from the Fred Hutch Cancer Center, to discuss the latest updates in multiple myeloma from EHA 2026.

Join us as we dived into:

The CEPHEUS study update, reaffirming the standard of care with quadruple therapy upfront, specifically D-VRd
Insights on the efficacy of teclistamab in early relapse refractory settings, including updates from the MajesTEC-3 and MajesTEC-9 studies.
The promising data around talquetamab from the MonumenTAL-3 study, highlighting its significant progression-free survival (PFS) improvement.
An overview of mezigdomide, a new immunomodulatory agent, and its impact on treatment strategies for anti-CD38 and lenalidomide-refractory patients.

We emphasized the importance of managing side effects and optimizing treatment sequences to ensure our patients can stay on these innovative therapies longer and safely.

Tune in for an informative discussion packed with the latest research and clinical insights in the world of oncology!

Listen to us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!

#MultipleMyeloma, #EHA2026, #BispecificAntibodies, #CELMoDs, #OncologyBrothers

EHA2026 Multiple Myeloma Highlights: CEPHEUS, MajesTEC-3, MajesTEC-9, MonumenTAL-3, SUCCESSOR-2

Oncology Brothers: Practice-Changing Cancer Discussions

EHA2026 Multiple Myeloma Highlights: CEPHEUS, MajesTEC-3, MajesTEC-9, MonumenTAL-3, SUCCESSOR-2